Dr. Antoaneta Vladimirova
Antoaneta
Vladimirova, Ph.D., M.Sc. is currently Director, Medical AI, at Roche DIS.
Antoaneta was previously in Product Management lead roles at
Roche DIS, and Director, Scientific Applications,
Partnerships & Product Strategy at
Station X
(acquired by
Roche), Director, Scientific Liaison at
NextBio
(acquired by Illumina),
Scientific Manager & Program Manager at
Ingenuity
Systems
(acquired by
Qiagen), and Principal Scientist
at
Iconix Biosciences
(acquired by
Entelos).
She coauthored
Notch-induced E2A ubiquitination and degradation are controlled by
MAP
kinase activities,
Development of a large-scale chemogenomics database to
improve drug candidate selection and to understand mechanisms
of chemical toxicity and action,
Pathway analysis tools and toxicogenomics reference databases for
risk
assessment,
Key Aspects of Toxicogenomic Data Analysis and Interpretation as a
Safety Assessment Tool to Identify and Understand Drug-Induced
Toxicity, and
In Silico Approaches Inform Drug Repurposing Strategies for the
Treatment of Ebola Infection.
Antoaneta earned her M.Sc. in Biotechnology and Genetic
Engineering at
Sofia University St. Kliment Ohridski, Bulgaria in 1991.
She earned her Ph.D. in Molecular and Cell Biology at New York
University in 1999 and earned her M.Sc. in Computer Science
at the New Jersey Institute of Technology in 2003.
Visit her
Facebook page.